Journal article
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
SJ Luen, G Viale, S Nik-Zainal, P Savas, R Kammler, P Dell'Orto, O Biasi, A Degasperi, LC Brown, I Láng, G MacGrogan, C Tondini, M Bellet, F Villa, A Bernardo, E Ciruelos, P Karlsson, P Neven, M Climent, B Müller Show all
Annals of Oncology | Published : 2023
Abstract
Background: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2−) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unexplained. Patients and methods: Genomic sequencing was applied to HR+HER2− tumours from patients enrolled in the Suppression of Ovarian Function Trial (SOFT) to determine genomic drivers that are enriched in young premenopausal women. Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample, n = 82). We d..
View full abstractGrants
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
This work was supported by a Susan G. Komen for the Cure Promise Grant [grant number CCR14299387 to SL], the National Health and Research Council (NHMRC) Australia [grant number 1084531] , the BCRF, NBCF Australia, and with the support from the family of Judy Eisman in Australia. The SOFT clinical trial receives financial support for trial conduct from Pfizer, the International Breast Cancer Study Group, the United States National Cancer Institute, the Breast Cancer Research Foundation (16-185, 17-187, 18-003, 19-011, 20-011) , Ipsen, TerSera, and AstraZeneca. Pfizer and Ipsen provided drug supply. Support for central pathology included Susan G. Komen for the Cure Promise Grant [grant number KG080081 to GV, MMR] and the Breast Cancer Research Foundation. Support for the coordinating group, IBCSG: Frontier Science and Technology Research Foundation, Swiss Group for Clinical Cancer Research (SAKK) , Cancer Research Switzerland, Oncosuisse, Cancer League Switzerland, Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK) , United States National Cancer Institute [United States NIH grant number CA075362] . Grant support of cooperative groups: Breast Cancer Trials Australia & New Zealand [NHMRC grant numbers 351161, 510788, 1105058] ; Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSGeICR-CTSU Partnership) [Cancer Research UK grant numbers CRUKE/03/022, CRUKE/03/023, A15955] ; National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre; and National Institute for Health Research/Cambridge Biomedical Research Centre; Alliance for Clinical Trials in Oncology [United States NIH grant number U10CA180821] ; SWOG [United States NIH grant number U10CA180888] ; ECOG-ACRIN Cancer Research Group [United States NIH grant number U10CACA180820, UG1CA233328] ; NRG Oncology [United States NIH grant numbers U10CA180868, U10CA180822, UG1CA189867] ; Canadian Cancer Trials Group [United States NIH grant number U10CA180863] ; and Canadian Cancer Society [grant number 704970] .